Cell Biotech Co., Ltd.

bioAffinity reports on a potential therapeutic approach that kills cancer cells without harm to normal cells SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment, today announced that David Elzi, Ph.D., bioAffinity Vice President of Research, will discuss his research into a possible mechanism by which the knock down of two genes kills cancer cells with little or no effect on normal cells at Cell Bio, a joint meeting of the American Society for Cell Biology (ASCB) and European Molecular Biology Organization (EMBO), in Washington, D.C., on Dec. 3-7, 2022. Dr. Elzi’s research supports the Company’s development of broad-spectrum cancer therapeutics. Dr. Elzi will present a poster titled “Reassessing Cobalamin Requirements in Cell Culture” on Monday, Dec. 5, 2022, from 12:15 p.m. to 1:45 p.m. EST at the Walter E. Reed Convention Center in Washington, D.C. “bioAffinity’s research is important in better understanding the foundation of our therapeutic platforms as it examines one potential mechanism for how silencing the genes CD320 and LRP2 together kills cancer cells but leaves normal cells unharmed,” Dr. Elzi said. “We previously reported on the Company’s design and use of siRNAs to kill multiple cancers at the cellular level, including prostate, lung, breast, brain and skin cancers, without harm to normal cells,” said bioAffinity President and CEO Maria Zannes. “We have reported on how to deliver the potential therapy. Dr. Elzi’s recent research that will be presented next week at Cell Bio looks at why it works.” Cell Bio 2022, the joint meeting of the ASCB and EMBO, will showcase a diverse global community of the brightest minds in cell biology in person, Dec. 3-7, 2022, in Washington, D.C. The unique meeting focuses on cell biology as the fundamental basis of biology as well as sessions on emerging interdisciplinary topics. About bioAffinity Technologies, Inc. bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment. The Company’s first product, CyPath® Lung, is a non-invasive test that has shown high sensitivity and specificity for the detection of early-stage lung cancer. Precision Pathology Services licensed and developed CyPath® Lung as a Laboratory Developed Test (LDT) and has begun test marketing in Texas. OncoSelect® Therapeutics, LLC, a subsidiary of bioAffinity Technologies, is advancing its discoveries shown in vitro to kill cancer cells without harm to normal cells. Research and optimization of the Company’s platform technologies are conducted in its laboratories at The University of Texas at San Antonio. Forward-Looking Statements This press release contains forward-looking statements, including statements regarding the anticipated use of proceeds from the Company’s offering of common shares. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

WASHINGTON, Nov. 30, 2022 /PRNewswire/ -- TIANGEN, a leading brand in the field of nucleic acid purification in China, has announced its participation in the Cell Bio 2022, the joint meeting of the American Society for Cell Biology (ASCB) and European Molecular Biology Organization (EMBO), from December 4 to 6, in Washington, DC, where it will bring a groundbreaking automated solution at Booth 621. The featured product that will be showcased at Booth 621 is the TGuide S16 Nucleic Acid Extractor. It could be a stunning product for most molecular biologists and cell biologists to learn about. "Researchers spend lots of their time on the repetitive hands-on experiment, while there hasn't been an optimal automated nucleic acid extraction solution in the global life science market. Automated extractors used mainly to serve industry. But now it's time for a change." said Kefei Sun, the GM of TIANGEN, "TIANGEN develops the TGuide S16, that is groundbreaking to this field". Apparently, the TGuide S16 is much smaller than all other extractors you may have ever seen. It processes up to 16 samples for a run and occupies less space than a piece of A4 paper. The design of the size, throughput and very importantly, the supporting reagent in prefilled format is all tailored for scientists to have the easy-to-use work experience. Although small in size, the TGuide S16, as the 5th generation of TIANGEN's TGuide S series extractors, adopts the upgraded magnetic bead-based extraction technique and series of formulas targeting all common samples in academic laboratories. The 10-year experience in automated purification should empower the TGuide S16 to produce reliable results to research users study all different sample types. Scientists may say farewell to the tedious manual DNA/RNA/plasmid/gel/PCR product purification protocols and walk into the new automated era. TIANGEN invites all interested scientists to apply for their newly launched Star Product Reviewer Recruitment Program, where they provide 1 on 1 product presentation and technical support, customized free trial opportunities, and exquisite gift packages. "We are very looking forward to meeting molecular biologists and cell biologists at Cell Bio 2022," said Kefei Sun, "Let the TGuide S16 bail the scientists out from tons of manual experiments and head for super productivity". About TIANGEN TIANGEN BIOTECH (BEIJING) CO., LTD. is a high-tech biological enterprise integrating R&D, production, sales, and customer service. It has been committed to providing customers with a total solution from sample storage to nucleic acid extraction and detection. Currently, it is a recognized leader in nucleic acid purification in the Chinese market. SOURCE TIANGEN BIOTECH (BEIJING) CO., LTD. Product information: Official website (Life Science): LinkedIn: TIANGEN (Search ID) or Contact: Linyu Sun Export Marketing Specialist linyu.sun@tiangen.com

SEOUL, South Korea, April 6, 2021 /PRNewswire/ -- Cell Biotech (KRX 049960), a probiotics & microbiome company, has acquired a European patent (Registration No. EP3453718) for the anticancer protein P8 originated from Lactobacillus rhamnosus for the new colorectal cancer drug "PP-P8". Following the Korean patent (Registration No. KR10-1910808) and Japanese patent (Registration No. JP6586248), it has also acquired patents in Europe, thereby gain a toehold for entry into the global pharmaceutical market by securing global intellectual property rights. Through this patent, it was found that the anticancer protein P8 has a remarkable therapeutic effect on colorectal cancer. In addition, in the non-clinical trial, the inhibitory effect of P8 on colorectal cancer cells was proven in mice and primates, and its safety against toxicity and side effects were also confirmed. It was developed to be produced from Pediococcus pentosaceus by genetically engineered strain. It is being developed as a treatment for colorectal cancer, and is awaiting approval for a phase I clinical trial from the South Korea's Ministry of Food and Drug Safety(MFDS). PP-P8 is a microbiome-based oral gene therapy, a new first-in-class colorectal cancer drug. It is a therapeutic agent using genetic techniques based on safe probiotics. Therefore, it is expected to be helpful in overcoming the shortcomings of chemical anticancer drugs, which have side effects caused by high concentration administration and long-term use. In addition to the patent for the anticancer protein P8, Cell Biotech has obtained Korean patents for the drug delivery system(DDS) and gene expression cassette. At the same time, patents in Europe, the United States, and Japan are in progress, expanding its position in the global pharmaceutical market. An official from Cell Biotech said, "In order to target the global colorectal cancer treatment market, which amounts to about $10 billion per year, patents are being registered not only in Korea but also in various countries. By preoccupying overseas patents, we will be reborn as a representative Korean company leading the development of new microbiome drugs and securing technological competitiveness." Company Codes: Korea:049960